X4 Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
XFOR Nasdaq 2830 www.x4pharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) - Jun 16th, 2025 6:00 am
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA - Jun 10th, 2025 6:00 am
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 2nd, 2025 2:05 pm
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress - May 14th, 2025 2:12 pm
X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ... - May 2nd, 2025 1:06 am
X4 Pharmaceuticals: Q1 Earnings Snapshot - May 1st, 2025 4:11 am
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - May 1st, 2025 4:01 am
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025 - Apr 30th, 2025 4:03 am
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 - Apr 24th, 2025 6:03 am
X4 Pharmaceuticals Announces Reverse Stock Split - Apr 24th, 2025 6:00 am
XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25… - Mar 27th, 2025 9:10 am
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Mar 26th, 2025 1:01 am
X4 Pharmaceuticals: Q4 Earnings Snapshot - Mar 25th, 2025 4:18 am
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Mar 25th, 2025 4:01 am
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025 - Mar 11th, 2025 6:00 am
X4 and taiba to distribute WHIM syndrome therapy in Middle East - Feb 20th, 2025 8:22 am
X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries - Feb 19th, 2025 8:53 am
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - Feb 19th, 2025 5:35 am
Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty - Feb 7th, 2025 3:52 am
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - Feb 6th, 2025 5:35 am